Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Canaccord Genuity analyst Sumant Kulkarni maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target ...
Cantor Fitzgerald analyst Kristen Kluska maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Overweight and lowers the price t...
Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(...
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Fr...
Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritt...
New data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced ...
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for p...
